Online Education
- Home
- Online Education
Important Note
You will need to login first in order to enroll or view an activity. Login Here
*Note: ✔ = Contact Hours Provided AND ✖ = No Contact Hours Provided
Gene Therapy for Providers 101
- Credits: 0.75 (ACCME), 0.75 (ANCC), 0.75 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 101 Details
Activity Number and Title
22HT57252 - Gene Therapy for Providers 101
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 45 minutes.
Purpose Statement
The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.
Activity Description
This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.
Target Audience
This accredited continuing education activity is designed for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
- Provide an overview of the goal of gene therapy for hemophilia
- Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
- Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
- Review known adverse effects from completed and ongoing clinical trials
- Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
- Discuss issues related to obtaining knowledgeable informed consent and counseling patients
Faculty
- Steven W. Pipe, MD
- Shelley Crary, MD, MSCS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-018-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Gene Therapy for Providers 201
- Credits: 1 (ACCME), 1.0 (ANCC), 1.0 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 201 Details
Activity Number and Title
22HT57253 - Gene Therapy for Providers 201
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this activity is 60 minutes.
Purpose Statement
The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.
Activity Description
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
Target Audience
This accredited continuing education activity is designed for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Identify patients who are eligible for AAV-mediated gene therapy
- Discuss key concepts involving education and shared decision-making for gene therapy
- Identify logistical/infrastructure requirements to procure, reconstitute and administer gene therapy at a dosing site
- Articulate the regional approach of preparing for gene therapy administration
- Distinguish the roles and responsibilities within the HTC team involved in the safety and efficacy assessments during short-and long-term monitoring before and after gene therapy
- Describe approaches to prevention, diagnosis, and treatment of vector-induced transaminitis after gene therapy
Faculty
- Rebecca Kruse-Jarres, MD, MPH
- Ulrike Margret Reiss, MD
- Courtney Dawn Thornburg, MD, MS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia and Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-019-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Gene Therapy for Providers 301
- Credits: 1 (ACCME), 1.0 (ANCC), 1.0 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 301 Details
Activity Number and Title
22HT57254 Gene Therapy for Providers 301
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 60 minutes.
Purpose Statement
The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.
Activity Description
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
Target Audience
This accredited continuing education activity is designed for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Discuss introductory concepts in hemophilia gene therapy
- Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
- Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
- Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
- Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion
Faculty
- Doris V. Quon, MD
- Lindsey A. George, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-020-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose
- Credits: 1.0 (ACCME), 1.0 (ANCC)
- Expiration Date: May 31, 2024
Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose Details
Activity Number and Title
21HT50146 Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose
Release Date
June 1, 2022
Expiration Date
5:00 PM Eastern, May 31, 2024
The estimated time to complete this activity is 60 minutes.
Purpose Statement
This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients.
Activity Description
This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content.
Target Audience
This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Identify the Curaçao criteria for determining the likelihood of Hereditary Hemorrhagic Telangiectasia (HHT) in an undiagnosed individual
- Describe HHT genetics and pathophysiology
- Discuss the international consensus screening guidelines for HHT management
- Review management of epistaxis, iron deficiency, and pulmonary arteriovenous malformations (PAVMs) in HHT
- Explain the importance of an HHT Center-driven multidisciplinary approach in caring for patients with HHT
Faculty
- Manjusha Kumar, MD
- Magdalena Lewandowska, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. This activity is provided for 0.15 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
The Partners in Bleeding Disorders Education Program is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc; Genentech, a member of the Roche Group; the National Hemophilia Foundation (NHF); and the Hemophilia Alliance.
Copyright © 2023 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits